Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Gene replacement therapy is an attractive approach for treatment of genetic disease, but may be complicated by the risk of a neutralizing immune response to the therapeutic gene product. There are examples of humoral and cellular immune responses against the transgene product as well as absence of such responses, depending on vector design and the underlying mutation in the dysfunctional gene. It has been unclear, however, whether transgene expression can induce tolerance to the therapeutic antigen. Here, we demonstrate induction of immune tolerance to a secreted human coagulation factor IX (hF.IX) antigen by adeno-associated viral gene transfer to the liver. Tolerized mice showed absence of anti-hF.IX and substantially reduced in vitro T cell responses after immunization with hF.IX in adjuvant. Tolerance induction was antigen specific, affected a broad range of Th cell subsets, and was favored by higher levels of transgene expression as determined by promoter strength, vector dose, and mouse strain. Hepatocyte-derived hF.IX expression induced regulatory CD4(+) T cells that can suppress anti-hF.IX formation after adoptive transfer. With a strain-dependent rate of success, tolerance to murine F.IX was induced in mice with a large F.IX gene deletion, supporting the relevance of these data for treatment of hemophilia B and other genetic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“mouse studies have shown liver-directed AAV gene therapy results in tolerogenic responses by the induction of Tregs,52, 53, 54, 55, 56, 57, 58, 59”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“It has been shown in multiple preclinical (160, 168 -171) and clinical studies (34) that liver-targeted AAV delivery induced immune tolerance of transgene products.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [34]
In the citing paper
“The immunogenic i.m. route was chosen for these experiments, as hepatic gene transfer typically results in tolerance induction to FIX (24, 38).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [24]
In the citing paper
“Expression of DTR under XCR1 promoter allowed specific depletion of XCR1+ DCs by administration of diphtheria toxin (DT) whereas expression of fluorescent protein allowed their easy detection and tracking.”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [24]
In the citing paper
“Fortunately, the immune response is not always against AAV-mediated gene transfer, evidenced by induction of regulatory T cells (Tregs) that suppress immune response and facilitate sustained transgene expression (34, 35).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic Cell Subsets and Lineages, and Their Functions in Innate and Adaptive Immunity
Liu, Y.-J. (2001) · Cell · doi:10.1016/s0092-8674(01)00456-1 · Cited by 1,004
Self-citationInduction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells
Weiner, H. L. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820117.x · Cited by 846 · cited 7×
“We do not know at this point whether TGF-β in hepatic tolerance is derived from regulatory Th3 cells or a different cell type.”
BackgroundInfluentialRoncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S., & Levings, M. K. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820105.x · Cited by 814 · cited 6×
“We do not know at this point whether TGF-β in hepatic tolerance is derived from regulatory Th3 cells or a different cell type.”
BackgroundInfluentialLimmer, A., Ohl, J., Kurts, C., Ljunggren, H.-G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., & Knolle, P. A. (2000) · Nature Medicine · doi:10.1038/82161 · Cited by 758 · cited 1×
“Liver transplants are often not rejected even across MHC barriers, and LSECs have been shown to represent specialized APCs that can induce T cell tolerance (40, 42).”
BackgroundLocal control of the immune response in the liver
Knolle, P. A., & Gerken, G. (2000) · Immunological Reviews · doi:10.1034/j.1600-0528.2002.017408.x · Cited by 603 · cited 3×
“) promotes tolerance rather than immunity to the transgene product (40).”
BackgroundSnyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554 · cited 3×
“IX vectors to adults with severe hemophilia B were initiated (4, 5, 8, 9).”
BackgroundSelf-citationAdeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500 · cited 1×
“AAV vector (serotype 2) was produced by triple transfection of HEK-293 cells, purified by CsCl-gradient centrifugation, and quantitated by dot blot hybridization as described (23).”
MethodNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478 · cited 1×
“IX as designed by Kay and colleagues (22).”
MethodJooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 5×
“Even with a ubiquitous promoter, hepatocytes are the major site of F.IX synthesis following portal infusion of AAV vector, which has a strong tropism for liver and does not appear to transduce other cell types within the liver or APCs (24, 43, 44).”
BackgroundInfluential
Research works printed but not linked: 2
- Manno, C.S., et al. 2003. A phase I safety study in patients with severe hemophilia B using adeno-associated viral (AAV) vector to deliver the gene for human factor IX to skeletal muscle. Blood . In press.
- Nakai, H., et al. 2000. A proposed rAAV-liver directed clinical trial for hemophilia B. Blood. 96 (Suppl.):798a-799a.
Cited by
Items 101–200 of 471
Colella, P., Sellier, P., Costa Verdera, H., Puzzo, F., van Wittenberghe, L., Guerchet, N., Daniele, N., Gjata, B., Marmier, S., Charles, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.002 · Cited by 74
“These findings are in agreement with previously published work showing that immune tolerance positively correlates with antigen expression levels in the liver.(6,72) No significant differences in hGAA content were observed in quadriceps of AAV8-treated mice (Figures S5C and S5D).”
ResultSelf-citationSack, B. K., Merchant, S., Markusic, D. M., Nathwani, A. C., Davidoff, A. M., Byrne, B. J., & Herzog, R. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037671 · Cited by 75
“We previously demonstrated tolerance induction to FIX by AAV gene transfer to the liver of hemophilic animals, which was particularly effective when using AAV8-a serotype that is highly effective in transducing murine hepatocytes [9,15].”
BackgroundResultInfluentialSelf-citationLong-term Amelioration of Feline Mucopolysaccharidosis VI After AAV-mediated Liver Gene Transfer
Cotugno, G., Annunziata, P., Tessitore, A., O’Malley, T. M., Capalbo, A., Faella, A., Bartolomeo, R., O’Donnell, P., Wang, P., Russo, F., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.257 · Cited by 80
Factor IX variants improve gene therapy efficacy for hemophilia B
Schuettrumpf, J., Herzog, R. W., Schlachterman, A., Kaufhold, A., Stafford, D. W., & Arruda, V. R. (2005) · Blood · doi:10.1182/blood-2004-08-2990 · Cited by 74
Self-citationQuintavalle, G., Castaman, G., Baldacci, E., Ferretti, A., Riccardi, F., Tagliaferri, A., & Santoro, C. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1660817 · Cited by 83
Hoffman, B. E., Martino, A. T., Sack, B. K., Cao, O., Liao, G., Terhorst, C., & Herzog, R. W. (2011) · Molecular Therapy · doi:10.1038/mt.2011.33 · Cited by 72
Self-citationAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
“• targeting of immune-privileged organs (37)”
BackgroundInfluentialGene therapy for immune tolerance induction in hemophilia with inhibitors
Arruda, V. R., & Samelson‐Jones, B. J. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13331 · Cited by 69
Self-citationAkbarpour, M., Goudy, K. S., Cantore, A., Russo, F., Sanvito, F., Naldini, L., Annoni, A., & Roncarolo, M. G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3032 · Cited by 65
Xu, L., Nichols, T. C., Sarkar, R., McCorquodale, S., Bellinger, D. A., & Ponder, K. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409249102 · Cited by 70
Development of gene transfer for induction of antigen-specific tolerance
Sack, B. K., Herzog, R. W., Terhorst, C., & Markusic, D. M. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.13 · Cited by 70
Self-citationMcIntosh, J. H., Cochrane, M., Cobbold, S., Waldmann, H., Nathwani, S. A., Davidoff, A. M., & Nathwani, A. C. (2012) · Gene Therapy · doi:10.1038/gt.2011.64 · Cited by 70
Advancements in AAV-mediated Gene Therapy for Pompe Disease
Salabarria, S. M., Nair, J., Clement, N., Smith, B. K., Raben, N., Fuller, D. D., Byrne, B. J., & Corti, M. (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190426 · Cited by 78
Tessitore, A., Faella, A., O’Malley, T. M., Cotugno, G., Doria, M., Kunieda, T., Matarese, G., Haskins, M. E., & Auricchio, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300325 · Cited by 73
Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors
Lu, Y., & Song, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909520106 · Cited by 65
Sabatino, D. E., Nichols, T. C., Merricks, E., Bellinger, D. A., Herzog, R. W., & Monahan, P. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-394596-9.00006-8 · Cited by 66
“…exon 17 knockout Reipert et al. 2009 Mouse Hemophilia B Targeted deletion Lin et al. 1997 • C57BL6 Mingozzi et al. 2003 • BALB/c Mingozzi et al. 2003 • C3H/HeJ Mingozzi et al. 2003 Hemophilia B Knock-in for human F.IX with crm+ missense mutation R333Q Jin et al. 2004 Hemophilia B Knock-in for…”
BackgroundInfluentialSelf-citationMcEachern, K. A., Nietupski, J. B., Chuang, W., Armentano, D., Johnson, J., Hutto, E., Grabowski, G. A., Cheng, S. H., & Marshall, J. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.901 · Cited by 68
“Furthermore, when harboring a tissue-restricted promoter, AAV vectors result in a reduced risk of a host immune response to the expressed transgene product [20,21].”
BackgroundVaccines Based on Novel Adeno-Associated Virus Vectors Elicit Aberrant CD8+T-Cell Responses in Mice
Lin, J., Zhi, Y., Mays, L., & Wilson, J. M. (2007) · Journal of Virology · doi:10.1128/jvi.01253-07 · Cited by 66
“A paucity of both CD8 T-cell and B-cell responses to transgene products is observed when AAV vectors are targeted to the liver (9, 26).”
BackgroundNAYAK, S., CAO, O., HOFFMAN, B. E., COOPER, M., ZHOU, S., ATKINSON, M. A., & HERZOG, R. W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03548.x · Cited by 66
Self-citationSafety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
Haurigot, V., Mingozzi, F., Buchlis, G., Hui, D. J., Chen, Y., Basner-Tschakarjan, E., Arruda, V. R., Radu, A., Franck, H. G., Wright, J. F., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.73 · Cited by 66
Self-citationPotential for cellular stress response to hepatic factor VIII expression from AAV vector
Zolotukhin, I., Markusic, D. M., Palaschak, B., Hoffman, B. E., Srikanthan, M. A., & Herzog, R. W. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.63 · Cited by 65
Self-citationZiegler, R. J., Bercury, S. D., Fidler, J., Zhao, M. A., Foley, J., Taksir, T. V., Ryan, S., Hodges, B. L., Scheule, R. K., Shihabuddin, L. S., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.010 · Cited by 65
“…of immunotolerance to the expressed transgene product, including the lysosomal enzymes (cid:2) -galactosidase A, acid sphingomyelinase, and acid (cid:4) -glucosidase, has been demonstrated previously (Mingozzi et al ., 2003; Ziegler et al ., 2004; Barbon et al ., 2005; McEach-ern et al ., 2006).”
Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?
Wagner, D. L., Peter, L., & Schmueck-Henneresse, M. (2021) · Gene Therapy · doi:10.1038/s41434-021-00232-2 · Cited by 63
“High antigen expression in the liver has been shown to exhaust Teff and induce Treg cells directed against vectors and transgenes [11, 88].”
BackgroundJacobs, F., Snoeys, J., Feng, Y., Craeyveld, E. V., Lievens, J., Armentano, D., Cheng, S. H., & Geest, B. D. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303096 · Cited by 64
High, K. A., & Aubourg, P. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_18 · Cited by 60
Self-citationEfficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9
Singh, K., Evens, H., Nair, N., Rincón, M. Y., Sarcar, S., Samara-Kuko, E., Chuah, M., & VandenDriessche, T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.023 · Cited by 68
Vigna, E., Amendola, M., Benedicenti, F., Simmons, A. D., Follenzi, A., & Naldini, L. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.11.017 · Cited by 60
Aronson, S. J., Bakker, R. S., Shi, X., Duijst, S., ten Bloemendaal, L., de Waart, D. R., Verheij, J., Ronzitti, G., Elferink, R. P. J. O., Beuers, U. H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.021 · Cited by 66
Gardner, M. R., Fetzer, I., Kattenhorn, L. M., Davis-Gardner, M. E., Zhou, A. S., Alfant, B., Weber, J. A., Kondur, H. R., Martinez-Navio, J. M., Fuchs, S. P., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.004 · Cited by 60
Complexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
“Adequate levels of transgene expression from hepatocytes (as determined by vector dose, promoter strength, and codon-usage, among other factors) induce immune tolerance through a combination of mechanisms [67, 82-84].”
BackgroundInfluentialSelf-citationYasuda, M., Bishop, D. F., Fowkes, M. E., Cheng, S. H., Gan, L., & Desnick, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.250 · Cited by 60
Immune tolerance in haemophilia: the long journey to the fork in the road
DiMichele, D. M. (2012) · British Journal of Haematology · doi:10.1111/bjh.12028 · Cited by 60
“Immunological tolerance with hepatic gene transfer has been achieved in a haemophilia B mouse model (Mingozzi et al, 2003; Dobrzynski et al, 2006).”
BackgroundMatsui, H., Shibata, M., Brown, B., Labelle, A., Hegadorn, C., Andrews, C., Chuah, M., VandenDriessche, T., Miao, C. H., Hough, C., et al. (2009) · Blood · doi:10.1182/blood-2009-03-202267 · Cited by 60
Annoni, A., Cantore, A., Della Valle, P., Goudy, K., Akbarpour, M., Russo, F., Bartolaccini, S., D'Angelo, A., Roncarolo, M. G., & Naldini, L. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302857 · Cited by 58
“Others and we have already shown that hepatocyte ‐ targeted expression of an Ag by different types of vectors favours the induction of tolerance mediated by Ag ‐ speci fi c Foxp3 þ Tregs (Annoni et al, 2009; Cao et al, 2007; Matrai et al, 2011; Mingozzi et al, 2003).”
Weir, G. A., Middleton, S. J., Clark, A. J., Daniel, T., Khovanov, N., McMahon, S. B., & Bennett, D. (2017) · Brain · doi:10.1093/brain/awx201 · Cited by 65
“However, strategies to modulate any potential immune re- sponse [e.g. tolerance induction or immune suppression (Mingozzi et al., 2003; Sack and Herzog, 2009)] to GluCl would have to be considered as part of any transla- tional pathway.”
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
Samelson-Jones, B. J., & Arruda, V. R. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.007 · Cited by 58
Self-citationIn Vivo Mouse Models for Hepatitis B Virus Infection and Their Application
Du, Y., Broering, R., Li, X., Zhang, X., Liu, J., Yang, D., & Lu, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.766534 · Cited by 63
“Thus, this vector has a clean background and does not induce an obvious non-HBV immune response (59), making it a more suitable tool to establish persistent HBV infection (10).”
BackgroundSelf-citationImmune outcomes in the liver: Is CD8 T cell fate determined by the environment?
Wong, Y. C., Tay, S. S., McCaughan, G. W., Bowen, D. G., & Bertolino, P. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.033 · Cited by 62
“Injection of antigens via the portal route resulting in direct delivery to the liver [2], and targeting gene expression to the liver [3], both often lead to tolerance.”
BackgroundImmune Responses to AAV Capsid: Are Mice Not Humans After All?
Herzog, R. W. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300123 · Cited by 56
Self-citationGene therapy for the hemophilias
VandenDriessche, T., Collen, D., & Chuah, M. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00265.x · Cited by 64
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · Blood · doi:10.1182/blood-2012-05-423210 · Cited by 55
Self-citationA versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
“It has been shown in multiple preclinical (160, 168–171) and clinical studies (34) that liver-targeted AAV delivery induced immune tolerance of transgene products.”
BackgroundCresawn, K. O., Fraites, T. J., Wasserfall, C., Atkinson, M., Lewis, M., Porvasnik, S., Liu, C., Mah, C., & Byrne, B. J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.68 · Cited by 57
Prospects for gene therapy of haemophilia
Nathwani, A. C., Davidoff, A. M., & Tuddenham, E. G. D. (2004) · Haemophilia · doi:10.1111/j.1365-2516.2004.00926.x · Cited by 58
“There are no plans to extend this study because it appears that muscle targeted delivery of rAAV is more likely to evoke an immunological response to hFIX [29, 30 ].”
BackgroundLiu, Y.-L., Mingozzi, F., Rodriguéz-Colôn, S. M., Joseph, S., Dobrzynski, E., Suzuki, T., High, K. A., & Herzog, R. W. (2004) · Human Gene Therapy · doi:10.1089/1043034041648453 · Cited by 54
Self-citationOu, L., Przybilla, M. J., Ahlat, O., Kim, S., Overn, P., Jarnes, J., O’Sullivan, M. G., & Whitley, C. B. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.018 · Cited by 56
“In addition, targeting the liver has additional advantages, including (1) substantial clinical experience with liver-targeting gene therapy, and (2) hepatic transgene expression known to induce immune tolerance.(47,48)”
BackgroundImmune tolerance induction in haemophilia: evidence and the way forward
Michele, D. M. D. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04349.x · Cited by 59
Priming and Maintenance of Adaptive Immunity in the Liver
Kawashima, K., Andreata, F., Beccaría, C. G., & Iannacone, M. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090122-041354 · Cited by 64
Herzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
Self-citationSferra, T. J., Backstrom, K. C., Wang, C., Rennard, R., Miller, M. T., & Hu, Y. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.029 · Cited by 57
Doerfler, P. A., Todd, A. G., Clément, N., Falk, D. J., Nayak, S., Herzog, R. W., & Byrne, B. J. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.103 · Cited by 54
Self-citationSun, B., Zhang, H., Benjamin, D. K., Brown, T. T., Bird, A., Young, S. P., McVie-Wylie, A. J., Chen, Y.-T., & Koeberl, D. D. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.001 · Cited by 55
“Acquisition of tolerance to FIX required induction of regulatory CD4+ T cells, most likely CD25+/CD4+ T regulatory cells, which suppressed neutralizing antibody formation [25].”
BackgroundGreig, J. A., Peng, H., Ohlstein, J., Medina-Jaszek, C. A., Ahonkhai, O., Mentzinger, A., Grant, R. L., Roy, S., Chen, S.-J., Bell, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112268 · Cited by 55
“It has been suggested that delivery of the vector to liver, either by design or inadvertently, could induce immunologic tolerance to the transgene product, thereby diminishing immune toxicity [16,17,18,19,20,21,22,23,24].”
BackgroundResultImmune barriers to successful gene therapy
Wu, T.-L., & Ertl, H. C. J. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.005 · Cited by 57
Martino, A. T., Nayak, S., Hoffman, B. E., Cooper, M., Liao, G., Markusic, D. M., Byrne, B. J., Terhorst, C., & Herzog, R. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006376 · Cited by 54
“from an effector to a regulatory response [18,25].”
BackgroundMethodSelf-citationBoisgerault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Self-citationProgress and challenges of gene therapy for Pompe disease
Ronzitti, G., Collaud, F., Laforet, P., & Mingozzi, F. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.67 · Cited by 51
“The liver is a particularly attractive organ for the development of gene-based therapeutic approaches for PD and other genetic disease for a number of reasons including: (I) it is one of the body’s major biosynthetic organs, is highly vascularized and can efficiently secrete proteins into the bloodstream; (II) studies…”
BackgroundSelf-citationStem Cell Transplantation for Muscular Dystrophy: The Challenge of Immune Response
Maffioletti, S. M., Noviello, M., English, K., & Tedesco, F. S. (2014) · BioMed Research International · doi:10.1155/2014/964010 · Cited by 62
Role of regulatory T cells in tolerance to coagulation factors
CAO, O., LODUCA, P. A., & HERZOG, R. W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03417.x · Cited by 54
Self-citationPeng, B., Ye, P., Blazar, B. R., Freeman, G. J., Rawlings, D. J., Ochs, H. D., & Miao, C. H. (2008) · Blood · doi:10.1182/blood-2008-01-128413 · Cited by 54
Hyperactive PiggyBac Transposons for Sustained and Robust Liver-targeted Gene Therapy
Matteo, M. D., Samara-Kuko, E., Ward, N. J., Waddington, S. N., McVey, J. H., Chuah, M., & VandenDriessche, T. (2014) · Molecular Therapy · doi:10.1038/mt.2014.131 · Cited by 57
Creation of a mouse expressing defective human factor IX
Jin, D., Zhang, T.-P., Gui, T., Stafford, D. W., & Monahan, P. E. (2004) · Blood · doi:10.1182/blood-2004-01-0138 · Cited by 54
Ruzo, A., García, M., Ribera, A., Villacampa, P., Haurigot, V., Marcó, S., Ayuso, E., Anguela, X. M., Roca, C., Agudo, J., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.220 · Cited by 62
“It has been reported that AAV-driven hepatic expression promotes transgene-specific immune tolerance”
BackgroundChuah, M., Evens, H., & VandenDriessche, T. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12215 · Cited by 59
Bigger, B., Siapati, E. K., Mistry, A., Waddington, S. N., Nivsarkar, M. S., Jacobs, L., Perrett, R. M., Holder, M. V., Ridler, C. M., Kemball‐Cook, G., et al. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302638 · Cited by 49
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · PubMed · doi:10.1182/asheducation-2012.1.375 · Cited by 48
Self-citationBarbon, C. M., Ziegler, R. J., Li, C. Q., Armentano, D., Cherry, M., Desnick, R. J., Schuchman, E. H., & Cheng, S. H. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.011 · Cited by 52
Hu, C., & Lipshutz, G. S. (2012) · Gene Therapy · doi:10.1038/gt.2011.200 · Cited by 48
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 53
Physiological and tissue-specific vectors for treatment of inherited diseases
Toscano, M. G., Romero, Z. G., Muñoz, P., Cobo, M., Benabdellah, K., & Martín, F. (2010) · Gene Therapy · doi:10.1038/gt.2010.138 · Cited by 51
Zhang, J., Xu, L., Haskins, M. E., & Parker Ponder, K. (2004) · Blood · doi:10.1182/blood-2003-06-2181 · Cited by 50
“4) 421 410 169 746 (12 800-1 000 000) 80 30 (12-200)”
Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes
Hui, D. J., Basner-Tschakarjan, E., Chen, Y., Davidson, R. J., Buchlis, G., Yazicioglu, M., Pien, G. C., Finn, J. D., Haurigot, V., Tai, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.166 · Cited by 47
Self-citationEfficient Transfection of Hepatocytes Mediated by mRNA Complexed to Galactosylated Cyclodextrins
Symens, N., Méndez‐Ardoy, A., Díaz‐Moscoso, A., Sánchez‐Fernández, E. M., Remaut, K., Demeester, J., Fernández, J. M. G., Smedt, S. C. D., & Rejman, J. (2012) · Bioconjugate Chemistry · doi:10.1021/bc3001003 · Cited by 47
Tolerance Induction by Viral In Vivo Gene Transfer
Dobrzynski, E., & Herzog, R. W. (2005) · Clinical Medicine & Research · doi:10.3121/cmr.3.4.234 · Cited by 47
Self-citationDomenico, C. D., Napoli, D. D., Reyero, E. G. Y., Lombardo, A., Naldini, L., & Natale, P. D. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1112 · Cited by 46
Gene therapy strategies for hemophilia: benefits versus risks
Petrus, I., Chuah, M., & VandenDriessche, T. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1500 · Cited by 51
“Antigenspecific CD4+ T-cell tolerance could be demonstrated in mice, where no FIX antibodies or cytotoxic T-lymphocytes (CTLs) developed after liver-directed administration of AAV2-FIX vector particles, not even after subsequent immunological challenge [163,164].”
BackgroundGernoux, G., Gruntman, A. M., Blackwood, M., Zieger, M., Flotte, T. R., & Mueller, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.004 · Cited by 44
Rogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-25 · Cited by 45
“Hemophilia B mice with targeted deletion of murine F9 (‘HB’) had been bred on C3H/HeJ background for >10 generations [21].”
BackgroundMethodSelf-citationGuilbaud, M., Devaux, M., Couzinié, C., Le Duff, J., Toromanoff, A., Vandamme, C., Jaulin, N., Gernoux, G., Larcher, T., Moullier, P., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.234 · Cited by 45
Muscle as a Target for Supplementary Factor IX Gene Transfer
Hoffman, B. E., Dobrzynski, E., Wang, L., Hirao, L., Mingozzi, F., Cao, O., & Herzog, R. W. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.042 · Cited by 44
Self-citationCellular and genetic therapies for haemophilia
LILLICRAP, D., VANDENDRIESSCHE, T., & HIGH, K. (2006) · Haemophilia · doi:10.1111/j.1365-2516.2006.01259.x · Cited by 45
Self-citationArjomandnejad, M., Sylvia, K., Blackwood, M., Nixon, T., Tang, Q., Muhuri, M., Gruntman, A. M., Gao, G., Flotte, T. R., & Keeler, A. M. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.010 · Cited by 44
Breous, E., Somanathan, S., Bell, P., & Wilson, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.002 · Cited by 40
Greig, J. A., Wang, Q., Reicherter, A. L., Chen, S.-J., Hanlon, A. L., Tipper, C. H., Clark, K. R., Wadsworth, S., Wang, L., & Wilson, J. M. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.128 · Cited by 40
Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates
Verdera, H. C., Collaud, F., Riling, C. R., Sellier, P., Nordin, J. M. L., Preston, G. M., Cagin, U., Fabregue, J., Barral, S., Moya‐Nilges, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26744-4 · Cited by 45
Self-citationA review of gene therapy for haematological disorders
Nathwani, A. C., Davidoff, A. M., & Linch, D. C. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05231.x · Cited by 49
“An extension of this study with higher doses of rAAV-2 vector is not likely to be performed because of the possibility of provoking a neutralizing antibody response to human FIX, as observed in animal models (Nathwani et al, 2001b; Mingozzi et al, 2003).”
BackgroundGene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Herzog, R. W., Kaczmarek, R., & High, K. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.043 · Cited by 43
Self-citationAhangarani, R. R., Janssens, W., VanderElst, L., Carlier, V. A., VandenDriessche, T., Chuah, M., Weynand, B., Vanoirbeek, J., Jacquemin, M. G., & Saint‐Remy, J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901777 · Cited by 42
“It may also represent a novel mechanism whereby the immune response toward a therapeutically relevant protein can be suppressed or prevented following gene therapy, distinct from what has been reported previously following hepatic gene delivery (53).”
ResultNichols, T. C., Hough, C. A., Agersø, H., Ezban, M., & Lillicrap, D. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13301 · Cited by 46
Samelson‐Jones, B. J., & Arruda, V. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00618 · Cited by 43
“This was first demonstrated in HB mice that were tolerized to human (h) factor IX (FIX) after AAV gene therapy (55), but has subsequently been demonstrated in several other disease models including HA, which is discussed in detail below.”
BackgroundSelf-citationRuozi, G., Bortolotti, F., Mura, A., Tomczyk, M., Falcione, A., Martinelli, V. C., Vodret, S., Braga, L., Ferro, M. D., Cannata, A. N., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo0699 · Cited by 42
“We generated liver-specific AAV vectors by cloning each factor’s coding sequence under the control of the human -1 antitrypsin (hAAT) promoter, which ensures exclusive expression in hepatocytes (44, 45), and we packaged the vector DNAs using the liver-specific AAV8 (Fig.”
MethodHost and Vector-dependent Effects on the Risk of Germline Transmission of AAV Vectors
Favaro, P., Downey, H. D., Zhou, J. S., Wright, J. F., Hauck, B., Mingozzi, F., High, K. A., & Arruda, V. R. (2009) · Molecular Therapy · doi:10.1038/mt.2009.56 · Cited by 40
Self-citationKumar, P., & Chan, W. (2011) · Current Gene Therapy · doi:10.2174/156652311794940782 · Cited by 45
“Induction of immunity against the transgene is a major hurdle to long-term efficacy of LV-mediated gene therapy [68-71].”
BackgroundPrevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B
Nayak, S., Sarkar, D., Perrin, G. Q., Moghimi, B., Hoffman, B. E., Zhou, S., Byrne, B. J., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00244 · Cited by 40
“IX than other strain backgrounds such as C57BL/6 or BALB/c (Mingozzi et al., 2003; Wang et al., 2005; Cao et al., 2006, 2009a; Verma et al., 2010).”
BackgroundSelf-citationImmune Implications of Gene Therapy for Hemophilia
Herzog, R., & Dobrzynski, E. (2004) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2004-825635 · Cited by 44
Self-citationPerrin, G. Q., Zolotukhin, I., Sherman, A., Biswas, M., de Jong, Y. P., Terhorst, C., Davidoff, A. M., & Herzog, R. W. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.83 · Cited by 40
Self-citationImmunomodulation for inhibitors in hemophilia A: the important role of Treg cells
Miao, C. H. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.33 · Cited by 40
The Liver as a Target Organ for Gene Therapy: State of the Art, Challenges, and Future Perspectives
Jacobs, F., Gordts, S. C., Muthuramu, I., & Geest, B. D. (2012) · Pharmaceuticals · doi:10.3390/ph5121372 · Cited by 48
“This transcriptional targeting has been shown to be a successful strategy to avoid the development of a humoral immune response against a potentially immunogenic transgene product in several studies [58–62,64,65].”
BackgroundHarnessing the liver to induce antigen-specific immune tolerance
Gottwick, C., Carambia, A., & Herkel, J. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00942-8 · Cited by 43
Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
Basner-Tschakarjan, E., Bijjiga, E., & Martino, A. T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00028 · Cited by 39
Metadata
- Authors
- Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Herzog, Roland W.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2003-05-01
- Volume
- 111
- Issue
- 9
- Pages
- 1347-1356
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC154443
- OpenAlex
- W4250446838
- Cited by
- 466
- References
- 44
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 19 · 2023: 11 · 2022: 17 · 2021: 16 · 2020: 19 · 2019: 21 · 2018: 24 · 2017: 29 · 2016: 13 · 2015: 18 · 2014: 21 · 2013: 17 · 2012: 23
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Hemophilia Foundation
- Hemophilia of Georgia
- National Institutes of Health (5r01hl061921-02)
- National Heart, Lung, and Blood Institute (R01 HL61921)
- National Institute of Allergy and Infectious Diseases (R01 AI/HL 51390-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune tolerance, coagulation factor IX, AAV gene delivery, hepatic gene transfer, gene replacement therapy, hemophilia B, regulatory T cells, T cell tolerance, transgene expression, secreted antigens, humoral immune response
- MeSH terms
- Dependovirus, Animals, Antibodies, Hemophilia B, Factor IX, Humans, Immune Tolerance, Liver, Mice, Inbred Strains, Promoter Regions, Genetic, Receptors, Antigen, T-Cell, T-Lymphocytes, Genetic Therapy, Interleukin-4, Gene Transfer Techniques, Mice, Knockout, fas Receptor, Adoptive Transfer, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.